1. Home
  2. IMXI vs URGN Comparison

IMXI vs URGN Comparison

Compare IMXI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$15.36

Market Cap

456.2M

Sector

Technology

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$22.81

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMXI
URGN
Founded
1994
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
456.2M
1.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
IMXI
URGN
Price
$15.36
$22.81
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$16.67
$28.50
AVG Volume (30 Days)
241.4K
888.2K
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$625,123,000.00
$96,516,000.00
Revenue This Year
N/A
$27.96
Revenue Next Year
$0.95
$123.02
P/E Ratio
$11.91
N/A
Revenue Growth
N/A
8.00
52 Week Low
$8.58
$3.42
52 Week High
$21.41
$30.00

Technical Indicators

Market Signals
Indicator
IMXI
URGN
Relative Strength Index (RSI) 60.67 47.75
Support Level $15.35 $21.62
Resistance Level $15.51 $24.71
Average True Range (ATR) 0.06 1.54
MACD -0.02 -0.38
Stochastic Oscillator 39.62 18.53

Price Performance

Historical Comparison
IMXI
URGN

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: